NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Adcytherix

Adcytherix

Private
MarseilleHealthcare & Life Scienceshttps://www.adcytherix.com/

Last Round

Series A

Oct 16, 2025

Total Funding Raised

$154.2M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Adcytherix is a biopharmaceutical company that develops novel antibody-drug conjugates (ADCs) for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADConcologydrug discoverytargeted cancer therapybiotechnologypayload engineeringbiopharmaclinical-stage biotechtherapeutic indexdrug licensingprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Adcytherix Comps

Public and private peers based on sector, stage, and business model.

Adcytherix comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Adcytherix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 16, 2025
SeedJun 11, 2024

Key People

Founding team and executive leadership

Jaime Arango

Chief Financial Officer - CFO

Executive Team

Adcytherix Investors

Notable investors and investment history

Adcytherix investors
InvestorRounds
Surveyor CapitalSeries A
RA Capital ManagementSeries A, Seed
Andera PartnersSeries A
Pontifax Venture CapitalSeries A, Seed
BpifranceSeries A
Dawn BiopharmaSeries A
aMoonSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    Grew 50% QoQ, from 16 to 24 employees.

  • Mar 1, 2026

    Simon Sturge appointed to reinforce governance during clinical growth phase.

Adcytherix Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Adcytherix Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Adcytherix's valuation, stock price, and market status.

Firmographic Details

HeadquartersMarseille
Employee Range24
Year Founded2024
Last FundingOct 16, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.